Race OncologyRace Oncology Ltd (ASX:RAC)hascontinued its hard...

Race Oncology

Race Oncology Ltd (ASX:RAC)hascontinued its hard work into its Zantrene studies.

PHASE 1B trial highlights have shown encouraging clinical responses in heavily pre-treated patients, with three of six patients successfully bridged to stem cell transplant. The company is now advancing to Phase 2 – efficacy stage with open label study results to be reported in stages.

Encouragingly, the company reported that Zantrene with immunotherapy shrinks melanoma tumours that do not respond to immunotherapy alone.

There is a lot of news on the horizon for RAC, including:

• Pre-clinical - in vitro– updates on AML, breast cancer, multiple myeloma, kidney cancer and cardioprotection.
• Pre-clinical - in vivo– animal studies in breast cancer, multiple myeloma and kidney cancer and animal work assessing cardioprotection from carfilzomib-induced heart damage.
• Clinical– first patient treatment in the extramedullary AML clinical trial, progress updates on AML Phase 2 trial at Chaim Sheba, Israel, clinical trial plan for cardioprotection in breast cancer patients, clinical trial plan FTO-focused solid tumour trials.

* -com -au / companies/news/989190/the-companies-aiming-to-beat-cancer-serve-up-the-highlights-in-the-june-quarter-989190.html